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Summary 
QUESTIONS UNDER STUDY: This pilot study aimed to assess the 
feasibility, acceptance and costs of an ultrasound scan screening 
programme for abdominal aortic aneurysms (AAA) in the elderly 
male population resident in Canton Ticino, Switzerland. 
METHODS: The target population were male patients aged 65–80 
years who attended the outpatient clinics of the Lugano Regional 
Hospital in 2013. The patients showing interest were contacted 
by phone to verify their eligibility and fix the appointment for the 
ultrasound scan of the abdominal aorta. Patients with recent 
examinations suitable for AAA detection were excluded. Aneu-
rysm was defined as an abdominal aorta with sagittal and/or 
axial diameter ≥ 30 mm. Patients’ characteristics and study 
results were presented as descriptive statistics. The chi-squared 
test was used to compare categorical variables with p <0.05 as a 
statistical significance threshold. 
RESULTS: 1634 patients received the screening information 
leaflet and 745 (45.6%) underwent the ultrasound scan. Among 
the 1091 eligible patients, the acceptance rate was 68.3%. A 
previously unknown AAA was diagnosed in 31 patients (4.2%, 
95% confidence interval 2.8–5.9%). Age and area of residence 
had a statistically significant impact on patient’s acceptance rate 
(p <0.05). The mean cost per screened patient was CHF 88. 
CONCLUSIONS: AAA screening of male patients aged 65–80 years 
is feasible with limited financial and organisational effort. Adher-
ence might be improved by a larger community-based pro-
gramme and involvement of general practitioners. 
Key words: screening; ultrasound scan; abdominal aortic aneu-
rysm; male population; Switzerland 
Introduction 
Rupture of an abdominal aortic aneurysm (AAA) is associated with a 
high overall mortality rate of 65–85% [1]. This holds true despite the 
introduction of modern, less invasive (endovascular) treatment meth-
ods [2]. Prevention of rupture is therefore paramount and a more than 
appealing concept. 
The vast majority of ruptured abdominal aortic aneurysms are larger 
than 55 mm in diameter. There is a strong male predominance of the 
disease, with men around four times more likely to have an AAA [3]. 
Normal aneurysm growth rate is around 1 cm in 3 years and the 
prevalence of the disease increases with age [4]. Before any rupture 
event, abdominal aortic aneurysms have a long asymptomatic latent 
phase.  
According to Frame and Carlson, a meaningful medical screening 
programme should meet the following criteria [5]: 
‒ The disease must have a significant impact on the quality of life. 
‒ Acceptable methods of treatment are available. 
‒ There must be a latent, asymptomatic period during which detec-
tion and treatment significantly reduce morbidity and/or mortality. 
‒ The treatment in the asymptomatic phase must yield a therapeutic 
result higher than that obtained by delaying the treatment until 
symptoms appear. 
‒ A low-cost detection method is needed and the incidence of the 
disease must be sufficient to justify the cost of screening. 
Screening for AAA meets all these criteria. Several population-based 
randomised trials have evaluated ultrasound screening for AAA: two 
British studies (the Multicentre Aneurysm Screening Study [MASS] 
and the Chichester trial), and one each in Denmark (Viborg) and 
Western Australia [6–9]. The MASS trial probably provides the most 
robust evidence of a reduction in aneurysm-related mortality by 
almost 50% in the screened population of men aged from 65 to 75 
years. In the cost-effectiveness analysis, AAA screening proved to be 
cost-effective for men from 65 to 75 years of age, which was also so 
in the long term follow up [7]. 
Based on this evidence, the World Health Organization has included 
AAA screening among the interventions that proved to be cost effec-
tive, and many countries have organised national AAA screening 
programmes, including the UK, Italy, Denmark and Australia. Swit-
zerland has lagged behind and so far no established medical organisa-
tions or health authorities have promoted screening programmes on a 
cantonal or national level. 
For this reason, we implemented the present pilot study in order to 
verify the feasibility, acceptance and costs of an AAA ultrasound scan 
screening programme in Canton Ticino, Switzerland as a contribution 
to the discussion on a national level. About 1800 male patients aged 
from 65 to 80 years every year attend the various outpatient clinics of 
the Regional Hospital of Lugano and we chose these patients as the 
target population for this study. 
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Methods 
This was a pilot screening study assessing the feasibility, acceptance 
and costs of implementing an AAA screening programme at the 
Regional Hospital of Lugano, Switzerland. 
Selection and enrolment of patients 
The target study population consisted of all male patients aged from 
65 to 80 years attending the outpatient clinics of the Regional Hospital 
of Lugano, from January to December 2013. Inpatients were not 
considered for the study, nor were patients who attended our emer-
gency department. 
As a criterion for eligibility, patients had to have undergone no prior 
examinations suitable for AAA diagnosis in the past (regardless of 
whether the result was positive or negative), had no prior aortic sur-
gery, be able to understand the nature of the study and give informed 
consent, and be resident in Canton Ticino. Patients were invited to 
participate by the clinic clerks and received a leaflet with a summary 
of the information on the AAA screening programme. If there was no 
direct evidence of lack of eligibility and patients agreed to leave their 
contact details, the project secretary called patients by telephone two 
to three days later. The secretary informed patients by telephone about 
the details of the screening programme and checked their eligibility, 
as well as their willingness to participate. If the patient’s feedback was 
positive, the secretary fixed an appointment for the ultrasound scan 
and sent a confirmation letter with the appointment details. No second 
calls were foreseen for patients who could not be reached on the first 
call. General practitioners were not involved in the recruitment or 
information, but were informed about the scan results of their patients. 
Endpoints and methods of measurement 
Aortic aneurysm was defined as an enlargement of the transverse or 
anterior-posterior diameter of the aorta by ≥30 mm [8]. Ultrasound 
scans were performed with a Logic 9 ultrasound machine (General 
Electrics®, Milwaukee, USA) by a single, specifically trained radiolo-
gist with 30 years of experience. The presence of aneurysm-related 
risk factors was investigated by the radiologist after completion of the 
ultrasound scan. 
The following characteristics of patients recruited for the screening 
programme were recorded: the patient’s age and aneurysm-related risk 
factors such as tobacco use, family history of AAA, dyslipidaemia, 
arterial hypertension, obesity and chronic pulmonary disease. The 
results of the ultrasound scan were documented in terms of maximal 
transverse and sagittal aortic diameter (outer-to-outer measurement). 
In the event of unwillingness to participate, the patient's reasons for 
refusal were documented. Possible exclusion criteria were document-
ed, as were reasons for failure to contact the patient. Patients who 
were found to have an aneurysm between 3 and 5 cm in diameter were 
reported to their general practitioner with the recommendation to 
organise an ultrasound scan follow-up, whereas patients with an 
aneurysm diameter >5 cm were referred to a vascular surgeon. The 
pharmacological approach, risk factor management and vascular 
workup were referred to the patient’s general practitioner. 
Statistics 
No statistical assumptions were made for the sample size as this was a 
feasibility study aiming at the inclusion of as many patients as possi-
ble over a given time. Descriptive statistics were used for demograph-
ic data, eligibility, risk factors, response to screening invitation, 
reasons for refusal, failure to perform the ultrasound scan, and ultra-
sound results. Proportions were reported with the relevant 95% confi-
dence intervals (CI). The chi-square test was used to compare the 
distribution of categorical variables. A p-value of less than 0.05 was 
considered statistically significant. 
Ethics 
The study was reviewed and approved by the competent ethics com-
mittee and was conducted in accordance with the principles stated in 
the Declaration of Helsinki. Patients agreeing to participate were 
asked to sign the informed consent form for the study. 
Results 
The clinic clerks offered the summary information leaflet to 1634 
patients attending the various outpatient clinics of the Regional Hospi-
tal of Lugano, Switzerland. Two hundred and forty-eight patients 
(15%) immediately refused any further contact and 295 (21%) of the 
remaining 1386 were ineligible for the study because of the availabil-
ity of recent examinations allowing assessment of the aorta. 
Three hundred and forty-six (32%) of the 1091 eligible patients con-
tacted by telephone to arrange the appointment for the ultrasound scan 
did not confirm their participation or did not attend the scheduled 
visit; 745 (68%) underwent the planned ultrasound scan of the ab-
dominal aorta. The study flow is summarised in figure 1. A previously 
unknown AAA was diagnosed in 31 screened patients (4.2%, 95% CI 
2.8–5.9). 
 
 
Figure 1: Study eligibility and recruitment. AAA = 
Abdominal aortic aneurysm. 
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Figure 2: Aortic diameters and subsequent management strategy in 
the screened patients. AAA = Abdominal aortic aneurysm. 
 
 
 
In 7 of the 745 patients examined with ultrasound, neither the sagittal 
nor the axial diameter of the infrarenal abdominal aorta could be 
assessed, because of meteorism or obesity. In 27 (3.6%) patients, an 
aortic diameter of 3–4 cm was detected. In three patients (0.4%) the 
infrarenal aorta had a diameter of 4–5 cm and one patient (0.1%) had 
an AAA of >5 cm in diameter. Ultrasound examination follow-up was 
recommended every two years for patients with aneurysms 3–4 cm in 
diameter, and every year for those with aneurysms of 4–5cm (fig. 2). 
The patient with an abdominal aortic diameter of more than 5 cm 
underwent open surgical repair with no postoperative complications. 
The study was not designed to estimate AAA prevalence. However, 
for 1031 patients the information about presence/absence of AAA 
could be obtained, either from previous recent examinations or the 
study screening results; it could not be assessed in the remaining 603 
patients because of early refusal or drop-out. The available data show 
a prevalence of AAA of 9.3% (96/1031, 95% CI 7.6–11.3%). 
If the patients immediately declining the screening invitation on the 
first contact and those refusing to participate on the following phone 
call are considered, the overall refusal rate was 594/1634 patients 
(36%). Almost half of these patients (248/594, 42%) did not provide 
specific reasons for declining the invitation to undergo the AAA 
screening, and the most frequent justifications indicated were lack of 
interest (186/594, 31%), higher priority given to other health problems 
or medical investigations (59/594, 10%), being under constant medical 
oversight already (38/594, 6%), logistical problems (37/594, 6%), and 
decision subject to prior general practitioner’s advice (27/594, 5%). 
The impact of age and area of residence on patient participation in the 
screening programme, assessed in all 1634 patients, shows that older 
patients have a statistically lower probability of undergoing AAA 
screening and that patients living in the Lugano area had a higher 
probability of participating in the screening programme compared to 
other regions of the canton Ticino (p<0.05). The influence of age and 
area of residence is also apparent when only the drop-outs due to 
patient refusal are considered out of the 1091 eligible patients (p = 
0.0004 and p =0.0001, respectively) (tables 1 and 2). 
 
 
Table 1: Abdominal aortic aneurysm screening acceptance rate by age category 
(eligible patients). 
Age (years) Patients  
undergoing  
AAA screening 
Patients  
refusing  
AAA screening 
Total 
65–70 73.8% (335) 26.2% (119) 100% (454) 
71–75 67.9% (247) 32.1% (117) 100% (364) 
76–80 59.7% (163) 40.3% (110) 100% (273) 
Total 745 346 1091 
AAA = abdominal aortic aneurysm 
p = 0.0004 
 
 
 
 
Table 2: Abdominal aortic aneurysm screening acceptance rate by area of 
residence (eligible patients). 
Area of residence Patients  
undergoing AAA 
screening 
Patients  
refusing  
AAA screening 
Total 
Lugano area 71.2% (597) 28.8% (241) 100% (838) 
Locarno 48.2% (13) 51.8% (14) 100% (27) 
Bellinzona area 65.6% (59) 34.4% (31) 100% (90) 
Leventina 66.7% (6) 33.3% (3) 100% (9) 
Mendrisio area 58.4% (59) 41.6% (42) 100% (101) 
Riviera 58.3% (7) 41.7% (5) 100% (12) 
Vallemaggia 33.3% (1) 66.7% (2) 100% (3) 
Blenio 20.0% (2) 80.0% (8) 100% (10) 
Other 100% (1) – 100% (1) 
Total 745 346 1091 
AAA = abdominal aortic aneurysm 
p = 0.0001 (Lugano compared with other areas of the canton) 
 
The total cost of the screening programme, including information 
leaflets, letters to the general practitioners, administrative support, and 
medical and nursing staff involvement was 65 549 Swiss francs 
(CHF). The corresponding mean cost per screened patient was CHF 
88. The number of patients to be screened to detect one previously 
unknown AAA was 24. The average cost of each new AAA diagnosis 
through the screening programme was CHF 2114.5. 
Discussion 
To date several randomised trials have demonstrated the efficacy of 
AAA screening in terms of reduction in AAA-related mortality at a 
reasonable cost and with a number needed to screen (NNS) amongst 
the lowest of all the existing screening programmes. As a result of the 
gathered evidence, several national societies of vascular surgery, such 
as the Canadian Society of Vascular Surgery, recommend AAA 
screening of the male population aged from 65 to 75 years [10]. Other 
countries started screening programmes years ago (Denmark, the UK, 
Germany, Italy). 
In Switzerland, no abdominal aortic aneurysm screening programme 
has been implemented at a cantonal or national level so far. Meyer et 
al. published the initial results of a computer-based alert system that 
stimulated an ultrasound scan booking for male patients over 60 years 
of age each time a doctor accessed noninvasive arterial work-up data 
[11]. This method is not adopted throughout the whole country. 
We conducted this pilot feasibility study with the aim of encouraging 
discussion on the advisability and implications of a large-scale screen-
ing programme, through the analysis of the technical and logistical 
requirements, the acceptance by the target population, and the associ-
ated costs. 
Our enrolment system, basically including only the delivery of an 
information leaflet, one phone contact and possibly a later interview 
with a physician involved in the study, turned out to be effective, 
efficient and inexpensive. The employment of a secretary at 50%, a 
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radiologist at 10% and of a clerk for preparation of patients prior to 
echography, allowed us to manage a pool of 1386 potential candidates 
and to screen 745 patients in one year. In terms of time consumption, 
in the initial phase each ultrasound scan took approximately 7 to 8 
minutes, whereas after a few months the screening rate increased to 
one patient every 5 minutes. Of course, the invitation only reached 
patients attending the outpatient clinics of our institution. This meant 
limited organisational effort, but it clearly does not allow the whole 
potential male target population to be reached. Our enrolment did not 
exclude patients with severe concomitant diagnoses that would ex-
clude them from undergoing any kind of aortic surgery or interven-
tion. Patients aged from 75 to 80 years were included in our study 
even if screening in this age group has shown fewer benefits [9]. 
These two factors in patient enrolment might reduce the potential 
benefit in terms of risk reduction of mortality of the screening. Higher 
age results in reduced life expectancy and higher perioperative mortal-
ity with a negative impact on screening benefit [12]. We did not 
include patients older than 80 years of age for this reason. 
Considering all 1634 patients who were offered the information leaflet 
at the very first contact, the participation rate is 64%. In the literature, 
higher participation rates are reported for large multicentre studies 
such as the Viborg Vascular Screening (74.7%) and the MASS Multi-
centre Aneurysm Screening Study (80.3%) [6, 13]. The reason for the 
lower acceptance is probably multifactorial. From the analysis of the 
collected data we identified two factors having a statistically signifi-
cant relationship with patient participation (area of residence and age); 
there are other probable causes that we have not been able to assess 
objectively, but which we feel should be considered. The delivery of 
the information leaflet by the clinic clerk did not allow personal 
explanation and emphasis on the usefulness of the screening pro-
gramme by a doctor. This might have negatively influenced the uptake 
of our screening programme. Moreover, the invitation to our screening 
was based on a single call, whereas in most screening programmes 
patients might receive repeated calls. Another suspected limiting 
factor is the attitude of the general practitioners towards the screening 
programme: the lack of their direct involvement is likely to have 
resulted in a less supportive behaviour or even to have led some of 
them to perceive our invitation, addressed directly to the subjects, as 
interfering with their patient management. As we did not systematical-
ly seek further contact after a patient’s refusal to participate, we 
received information about the general practitioner’s reactions only 
occasionally. Therefore, we are unable to determine how many pa-
tients were discouraged from undergoing the proposed screening or 
how many benefitted from AAA screening anyhow, even if not 
through the participation in our study. A closer collaboration with the 
general practitioners would also have allowed the exclusion of pa-
tients with a severe concomitant diagnosis, who are unable to undergo 
any kind of aortic intervention. 
If we consider all patients for whom the presence or absence of AAA 
could be determined, either by prior recent investigations or by the 
study screening, the resulting overall prevalence of AAA of 9.3% 
(95% CI 7.6–11.3%) appears higher than that reported in large studies 
such as the Western Australia [9] and the MASS [6] trials (7.2% and 
4.9%, respectively) [6, 9]. This difference is probably due to the fact 
that the target population of our study consisted of medicalised sub-
jects attending the hospital clinics, including cardiology and angiolo-
gy. On the other hand, the AAA prevalence we observed in the 745 
patients with no prior investigations suitable for AAA detection who 
had the ultrasound screening was 4.2% (95% CI 2.8–5.9%), in line 
with the published results from the MASS and Viborg trials [6, 8]. We 
are not aware of any recent studies describing the AAA prevalence in 
Switzerland. A recently published article from neighbouring northern 
Italy showed a AAA prevalence on ultrasound scan of 2.5% in a male 
invited group aged 60 to 85 years [14]. 
The average cost per screened patient was CHF 88. This cost includes 
the resources needed for contacting and selecting patients who were 
ineligible or eventually refused to participate. The cost of the ultra-
sound scan, which is, apart from the costs of elective aortic surgery in 
the screened population, the most important cost factor, seems compa-
rable to the cost in other countries. In Canada, for example, the cost of 
the ultrasound scan ranged from 32 to 98 Canadian dollars [10]. Initial 
screening cost 83.75 Danish kroner in the Viborg trial [8]. Of course 
the overall costs might be different in our screening programme if it 
were more community based. We cannot make any assumptions about 
this at present. 
The overall impression of the hospital staff involved in the study was 
that the AAA screening implied minimal organisational effort and 
very limited discomfort for the participating patients; however, patient 
discomfort was not included in the data collected and, therefore, it 
could not be objectively quantified. 
As to cost-effectiveness, the advantage in preventing aneurysm rup-
ture and the related potential risks and costs seem sufficient to justify 
the screening cost even if our study did not include a proper cost-
effectiveness analysis. In contrast to other countries where AAA 
ultrasound screening programmes proved to be cost-effective [7], we 
do not have this analysis for the Swiss healthcare system. In order to 
validate cost-effectiveness of our screening programme, further stud-
ies would be necessary, including advanced calculation models. 
In conclusion, AAA screening of the male population aged from 65 to 
80 years is feasible with limited financial and organisational effort. 
Uptake might be improved by offering a more community-based 
programme and by getting more support from the general practition-
ers. 
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